Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …

The emergence of immune checkpoint blockade therapies over the last decade has
transformed cancer treatment in a wide range of tumor types. Unprecedented and durable …

Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …

Background Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic
cancer-related death in developed countries and new treatments are needed. Previous …

Cancer immunotherapies enhance anti-tumor immune responses using checkpoint
inhibitors, such as PD-1 or PD-L1 inhibitors. Recent studies, however, have extended the …

Genomic instability remains an enabling feature of cancer and promotes malignant
transformation. Alterations of DNA damage response (DDR) pathways allow genomic …

Accumulating evidence suggests that exogenous cellular stress induces PD-L1 upregulation
in cancer. A DNA double-strand break (DSB) is the most critical type of genotoxic stress, but …